profit from every $100 of sales.
$0$100
Star Equity Holdings
$9.01-1.21% today
-10.3% in 1 year
1-year low $9.011-year high $11.81
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Star Equity Holdings sold, what it kept, and what it did with the cash.
Sales went from $201 million in 2022 to $172 million in 2025, with -$5.92 million of profit last year.
SalesProfit
Star Equity Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Star Equity Holdings | No profit yet | ||
 Illumina | 39.3× · Expensive | ||
 Labcorp Holdings | 34.4× · Expensive | ||
 Quest Diagnostics | 28.9× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Star Equity Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 201 | 161 | 140 | 172 | |
| 99 | 80 | 70 | 80 | |
| 9 | 1 | -4 | -4 | |
| 11 | 3 | -2 | -2 | |
| 7 | 2 | -5 | -6 | |
| 2.27 | 0.70 | -1.59 | -1.85 | |
| 49.4% | 49.8% | 50.1% | 46.4% | |
| 4.6% | 0.9% | -2.7% | -2.1% | |
| 3.5% | 1.4% | -3.4% | -3.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 68 | 61 | 53 | 113 |
| Cash | 27 | 23 | 17 | 10 |
| Total debt | 2 | 1 | 1 | 26 |
| Total liabilities | 22 | 12 | 12 | 48 |
| 46 | 49 | 40 | 66 | |
| 3 | 3 | 3 | 3 | |
| 15.5% | 2.2% | -7.3% | -3.2% | |
| 15.6% | 4.5% | -11.8% | -9.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 9 | 0 | -3 | -7 | |
| 1 | 0 | 0 | 2 | |
| 9 | 0 | -3 | -9 | |
| Dividends paid | – | – | 0 | 1 |
| 1 | 1 | 3 | 3 | |
| 2 | 1 | 1 | 1 |
Valuation
- –
- 11.1×
- –
- 0.5×
- 0.2×
- –
- –
- -26.7%
- -17.6%
- 0.0%
Profitability
- 46.4%
- -2.1%
- -3.4%
- -1.4%
- -5.0%
- -9.1%
- -10.0%
- -4.7%
- -5.8%
- –
Growth
- −5.0%
- –
- −11.5%
- –
- −10.9%
Financial health
- –
- 0.40
- 23.3%
- -267.3×
- 2.10
- 1.86
- 1.35
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 31%of 948
Bottom 19%of 871
Bottom 10%of 868
Bottom 2%of 985
What analysts expect
- Average price target
- $8.00
- Range
- $8.00 – $8.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.99 | -0.20 | −395.0% |
| Mar 17, 2026 | -0.10 | 0.14 | −171.4% |
| Nov 13, 2025 | 0.02 | 0.32 | −93.8% |
| Aug 8, 2025 | 0.12 | 0.17 | −29.4% |
| May 14, 2025 | -0.52 | -0.25 | −108.0% |
| Mar 20, 2025 | 0.15 | -0.17 | +188.2% |
| Nov 19, 2024 | -0.29 | -0.26 | −11.5% |
| Aug 13, 2024 | -0.29 | -0.25 | −16.0% |
News
N.Y. Knicks star Josh Hart relists Florida home for $5.7 millionMarketWatch · Nov 10, 2026Brewers star Christian Yelich is selling his hillside Malibu mansion for $30 millionMarketWatch · Nov 9, 20265-star analyst resets Nvidia stock target after Intel crashYahoo Finance · Nov 5, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
43No pass
Benjamin Graham
63Pass
Philip Fisher
46No pass
Peter Lynch
27No pass
Joel Greenblatt
0No pass
Charlie Munger
43No pass
Terry Smith
42No pass
Questions about Star Equity Holdings
Is Star Equity Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Star Equity Holdings AI analysis
What does Star Equity Holdings do?
Star Equity Holdings, Inc. provides healthcare solutions in the United States and internationally. It operates through four segments: Diagnostic Services, Diagnostic Imaging, Construction, and Investments. It is in Medical - Diagnostics & Research.
Does Star Equity Holdings pay a dividend?
Yes. In 2025 it paid out $740,000 in dividends.
Is Star Equity Holdings stock halal?
No. Star Equity Holdings does not pass our halal screen: its debt is 79% of its market value, at or above the 33% limit. How we check
How has Star Equity Holdings stock done over the past year?
Down 10.3% over the past twelve months, to $9.01. It traded between $9.01 and $11.81 and is 23.7% below its high.
Who are Star Equity Holdings's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Star Equity Holdings's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.